Skip to main content
Journal cover image

Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.

Publication ,  Journal Article
Hurwitz, MD; Halabi, S; Ou, S-S; McGinnis, LS; Keuttel, MR; Dibiase, SJ; Small, EJ
Published in: Int J Radiat Oncol Biol Phys
November 1, 2008

PURPOSE: Transperineal prostate brachytherapy (TPPB) can be used with external beam radiation therapy (EBRT) to provide a high-dose conformal boost to the prostate. The results of a multicenter Phase II trial assessing safety of combination of EBRT and TPPB boost with androgen suppression (AST) in treatment of intermediate-risk prostate cancer are present here. MATERIALS AND METHODS: Patients had intermediate-risk prostate cancer. Six months of AST was administered. EBRT to the prostate and seminal vesicles was administered to 45Gy followed by TPPB using either (125)I or (103)Pd to deliver an additional 100Gy or 90Gy. Toxicity was graded using the National Cancer Institute CTC version 2 and the Radiation Therapy Oncology Group late radiation morbidity scoring systems. RESULTS: Sixty-three patients were enrolled. Median follow-up was 38 months. Side effects of AST including sexual dysfunction and vasomotor symptoms were commonly observed. Apart from erectile dysfunction, short-term Grade 2 and 3 toxicity was noted in 21% and 7%, primarily genitourinary related. Long-term Grade 2 and 3 toxicities were noted in 13% and 3%. Two patients had Grade 3 dysuria that resolved with longer follow-up. The most common Grade 2 long-term toxicity was urinary frequency (5%). No biochemical or clinical evidence of progression was noted for the entire cohort. CONCLUSIONS: In a cooperative group setting, combination EBRT and TPPB boost with 6 months of AST was generally well tolerated with expected genitourinary and gastrointestinal toxicities. Further follow-up will be required to fully assess long-term toxicity and cancer control.

Duke Scholars

Published In

Int J Radiat Oncol Biol Phys

DOI

EISSN

1879-355X

Publication Date

November 1, 2008

Volume

72

Issue

3

Start / End Page

814 / 819

Location

United States

Related Subject Headings

  • Seminal Vesicles
  • Radiotherapy, Conformal
  • Radioisotopes
  • Radiation Injuries
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Palladium
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hurwitz, M. D., Halabi, S., Ou, S.-S., McGinnis, L. S., Keuttel, M. R., Dibiase, S. J., & Small, E. J. (2008). Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. Int J Radiat Oncol Biol Phys, 72(3), 814–819. https://doi.org/10.1016/j.ijrobp.2008.01.010
Hurwitz, Mark D., Susan Halabi, San-San Ou, Lamar S. McGinnis, Michael R. Keuttel, Steven J. Dibiase, and Eric J. Small. “Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.Int J Radiat Oncol Biol Phys 72, no. 3 (November 1, 2008): 814–19. https://doi.org/10.1016/j.ijrobp.2008.01.010.
Hurwitz MD, Halabi S, Ou S-S, McGinnis LS, Keuttel MR, Dibiase SJ, et al. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):814–9.
Hurwitz, Mark D., et al. “Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.Int J Radiat Oncol Biol Phys, vol. 72, no. 3, Nov. 2008, pp. 814–19. Pubmed, doi:10.1016/j.ijrobp.2008.01.010.
Hurwitz MD, Halabi S, Ou S-S, McGinnis LS, Keuttel MR, Dibiase SJ, Small EJ. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):814–819.
Journal cover image

Published In

Int J Radiat Oncol Biol Phys

DOI

EISSN

1879-355X

Publication Date

November 1, 2008

Volume

72

Issue

3

Start / End Page

814 / 819

Location

United States

Related Subject Headings

  • Seminal Vesicles
  • Radiotherapy, Conformal
  • Radioisotopes
  • Radiation Injuries
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Palladium
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Middle Aged